Determining Predictors of Early Response to Exenatide in Patients with Type 2 Diabetes Mellitus

Table 4

Contingency table quantifying the percentage change in HbA1c after 3 months of exenatide therapy from baseline against the proportion of participants who went on to respond and not to respond to exenatide by 6 months.

		Number of responders and nonresponders		value
		Responders	Nonresponders
Difference in HbA1c after 3 months of exenatide therapy compared to baseline HbA1c (%)	> 5	0	10	0.0001
	0 < ≤ 5	2	6	0.13
	0	2	3	0.65
	−5 ≤ < 0	4	10	0.041
	−10 ≤ < −5	7	9	0.29
	−15 ≤ < −10	7	6	0.85
	−20 ≤ < −15	13	3	0.033
	−25 ≤ < −20	11	2	0.037
	−25 <	17	0	0.0001

denotes the percentage difference. A reduction in HbA1c from baseline after 3 months of exenatide therapy is indicated by a − value. HbA1c: glycated haemoglobin.